In this episode of the VJDementia podcast, we’ll be discussing recent advances in the development of neflamapimod for the treatment of dementia with Lewy bodies (DLB). Neflamapimod has shown encouraging results in the Phase II RewinD-LB trial (NCT05869669), and its clinical development is now progressing toward Phase III. The agent was recently granted Innovative Licensing and Access Pathway (ILAP) designation in the UK for DLB, aiming to accelerate the route to market and patient access.

You will hear from James Galvin, MD, MPH, Miller School of Medicine, Miami, FL, on the key data from the RewinD-LB trial, and Jacqui Cannon, CEO of The Lewy Body Society, on the impact of the ILAP designation.